Subscribe
alessandro-zappalorto
Alessandro Zappalorto / Shutterstock.com
8 April 2020Big PharmaRory O'Neill

EMA unveils fast-track drug shortage monitoring

The EU’s drugs regulator has set up a fast-track system to monitor shortages during the COVID-19 pandemic.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Report slams big pharma influence in EU-funded project
28 May 2020   A new NGO report has sharply criticised the EU-funded Innovative Medicines Initiative as favouring Big Pharma over small businesses, particularly when it comes to IP.
Biotechnology
EMA backs switch to biosimilars
22 September 2022   Evidence shows medicines approved as biosimilars in the EU may be prescribed interchangeably | Additional ‘switch’ studies no longer not need to be carried out.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Big Pharma
Report slams big pharma influence in EU-funded project
28 May 2020   A new NGO report has sharply criticised the EU-funded Innovative Medicines Initiative as favouring Big Pharma over small businesses, particularly when it comes to IP.
Biotechnology
EMA backs switch to biosimilars
22 September 2022   Evidence shows medicines approved as biosimilars in the EU may be prescribed interchangeably | Additional ‘switch’ studies no longer not need to be carried out.

More on this story

Big Pharma
Report slams big pharma influence in EU-funded project
28 May 2020   A new NGO report has sharply criticised the EU-funded Innovative Medicines Initiative as favouring Big Pharma over small businesses, particularly when it comes to IP.
Biotechnology
EMA backs switch to biosimilars
22 September 2022   Evidence shows medicines approved as biosimilars in the EU may be prescribed interchangeably | Additional ‘switch’ studies no longer not need to be carried out.

More features

President Trump 2.0: Five major areas to watch
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?
Pfizer infringed haemophilia therapy patent, says court